Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00100243
Status:
COMPLETED
Last Update Posted:
2006-09-19
First Post:
2004-12-27
Brief Title:
Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
Sponsor:
PRAECIS Pharmaceuticals Inc
Organization:
PRAECIS Pharmaceuticals Inc
Study Overview
Official Title:
Phase 2 Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
Status:
COMPLETED
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 2 open-label study in subjects with androgen-independent prostate cancer who have progressed following treatment with an LHRH agonist Up to 22 subjects will be enrolled Enrollment will be monitored to ensure that not all subjects are enrolled based on rising prostate specific antigen PSA criterion only
Subjects will be treated with abarelix Plenaxis 100 mg intramuscularly IM every 2 weeks for 12 weeks total dose of 600 mg
Subjects will be treated with abarelix Plenaxis 100 mg intramuscularly IM every 2 weeks for 12 weeks total dose of 600 mg
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None